Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

Glancy Prongay & Murray LLP reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

Its UK #NationalApprenticeshipWeek, so we've put together a list of our top ten manufacturing apprenticeship schemes led by ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 ...

Water is the hidden ingredient in many products and production processes, but it is taking an increasingly central role as ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Seven rheumatology researchers have authored a paper questioning the utility of the 2024 National Academies’ broad definition of long COVID.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.